PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 92.29

Change

0.00 (0.00)%

Market Cap

USD 4.99B

Volume

1.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 27.48B
PODD Insulet Corporation

N/A

USD 16.52B
BRKR Bruker Corporation

N/A

USD 8.98B
MASI Masimo Corporation

N/A

USD 7.71B
TMDX TransMedics Group Inc

N/A

USD 4.17B
AXNX Axonics Modulation Technologie..

N/A

USD 3.60B
NARI Inari Medical Inc

N/A

USD 2.85B
LIVN LivaNova PLC

N/A

USD 2.80B
QDEL Quidel Corporation

N/A

USD 2.62B
IRTC iRhythm Technologies Inc

N/A

USD 2.37B

ETFs Containing PRCT

FYC First Trust Small Cap Gro.. 0.00 % 0.70 %

N/A

USD 0.35B
FYX First Trust Small Cap Cor.. 0.00 % 0.63 %

N/A

USD 0.92B
DTEC ALPS Disruptive Technolog.. 0.00 % 0.00 %

N/A

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 120.21% 69% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.21% 69% C- 81% B-
Trailing 12 Months  
Capital Gain 172.16% 66% D+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 172.16% 66% D+ 82% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.33% 68% D+ 78% C+
Dividend Return 25.33% 68% D+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.32% 65% D 39% F
Risk Adjusted Return 51.35% 94% A 79% B-
Market Capitalization 4.99B 96% N/A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.